Search

Your search keyword '"Guo, Minzhang"' showing total 29 results
Start Over Author "Guo, Minzhang"
29 results on '"Guo, Minzhang"'

7. Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Author

Cheng, Jiahan, primary, Guo, Minzhang, additional, Yang, Yushang, additional, Liu, Yilin, additional, Hu, Weipeng, additional, Shang, Qixin, additional, Li, Chuan, additional, Xia, Liang, additional, Wang, Yun, additional, Wang, Wenping, additional, Tian, Dong, additional, Yuan, Yong, additional, Hu, Yang, additional, and Chen, Longqi, additional

Published
2022
Full Text
View/download PDF

8. Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations

Author

He, Qihua, primary, Liu, Jun, additional, Cai, Xiuyu, additional, He, Miao, additional, Li, Caichen, additional, Liang, Hengrui, additional, Cheng, Bo, additional, Xia, Xiaojun, additional, Guo, Minzhang, additional, Liang, Peng, additional, Zhong, Ran, additional, Li, Feng, additional, Yu, Ziwen, additional, Zhao, Yi, additional, Ou, Limin, additional, Xiong, Shan, additional, Li, Jianfu, additional, Zhang, Jianrong, additional, He, Jianxing, additional, and Liang, Wenhua, additional

Published
2021
Full Text
View/download PDF

9. Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma

Author

Li, Qiwen, primary, Ma, Li, additional, Qiu, Bo, additional, Wen, Yuzhi, additional, Liang, Wenhua, additional, Hu, Wanming, additional, Chen, Naibin, additional, Zhang, Tian, additional, Xu, Shuangbing, additional, Chen, Lingjuan, additional, Guo, Minzhang, additional, Zhao, Yi, additional, Liu, Songran, additional, Guo, Jinyu, additional, Wang, Junye, additional, Wang, Siyu, additional, Wang, Xin, additional, Pang, Qingsong, additional, Long, Hao, additional, and Liu, Hui, additional

Published
2021
Full Text
View/download PDF

15. Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition

Author

Liang, Wenhua, primary, Guo, Minzhang, additional, Pan, Zhenkui, additional, Cai, Xiuyu, additional, Li, Caichen, additional, Zhao, Yi, additional, Liang, Hengrui, additional, Yang, Haiying, additional, Wang, Zhen, additional, Chen, Wenting, additional, Xu, Chuhong, additional, Yang, Xinyun, additional, Sun, Jianyu, additional, He, Ping, additional, Gu, Xia, additional, Yin, Weiqiang, additional, and He, Jianxing, additional

Published
2019
Full Text
View/download PDF

16. The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures

Author

He, Qihua, primary, Xin, Peiling, additional, Zhang, Mingzhe, additional, Jiang, Si, additional, Zhang, Jianrong, additional, Zhong, Shengyi, additional, Liu, Yang, additional, Guo, Minzhang, additional, Chen, Xuewei, additional, Xia, Xiaojun, additional, Pan, Zhenkui, additional, Guo, Chenye, additional, Cai, Xiuyu, additional, Liang, Wenhua, additional, and He, Jianxing, additional

Published
2019
Full Text
View/download PDF

17. Choice of surgical procedure – lobectomy, segmentectomy, or wedge resection – for patients with stage T1‐2N0M0 small cell lung cancer: A population‐based study

Author

Liu, Yang, primary, Shan, Lanlan, additional, Shen, Jianfei, additional, Liu, Liping, additional, Wang, Jinlin, additional, He, Jiaxi, additional, He, Qihua, additional, Jiang, Long, additional, Guo, Minzhang, additional, Chen, Xuewei, additional, Zeng, Haikang, additional, Xia, Xiaojun, additional, Peng, Guilin, additional, Liang, Wenhua, additional, and He, Jianxing, additional

Published
2019
Full Text
View/download PDF

18. Impact of examined lymph node counts on survival of patients with stage IA non-small cell lung cancer undergoing sublobar resection

Author

Liu, Yang, primary, Shen, Jianfei, additional, Liu, Liping, additional, Shan, Lanlan, additional, He, Jiaxi, additional, He, Qihua, additional, Jiang, Long, additional, Guo, Minzhang, additional, Chen, Xuewei, additional, Pan, Hui, additional, Peng, Guilin, additional, Shi, Honghui, additional, Ou, Limin, additional, Liang, Wenhua, additional, and He, Jianxing, additional

Published
2018
Full Text
View/download PDF

19. Direct comparison of autofluorescence bronchoscopy (AFB) and the combination of autofluorescence bronchoscopy and white light bronchoscopy (AFB + WLB) for detecting airway cancerous and precancerous lesions: a systematic review and meta-analysis

Author

Zhang, Jianrong, primary, Wu, Jieyu, additional, Xu, Zhiheng, additional, Yang, Yujing, additional, Liao, Hua, additional, Liang, Ziyan, additional, Jiang, Long, additional, Li, Jingpei, additional, Guo, Minzhang, additional, Chen, Xuewei, additional, Zeng, Yuan, additional, He, Qihua, additional, Liang, Wenhua, additional, and He, Jianxing, additional

Published
2018
Full Text
View/download PDF

21. Correlation between epidermal growth factor receptor mutations and nuclear expression of female hormone receptors in non-small cell lung cancer: a meta-analysis

Author

He, Qihua, Zhang, Mingzhe, Zhang, Jianrong, Chen, Ying, He, Jiaxi, Shen, Jianfei, Liu, Yang, Zhong, Shengyi, Jiang, Long, Yang, Chenglin, Zeng, Yuan, Guo, Minzhang, Chen, Xuewei, He, Jianxing, and Liang, Wenhua

Subjects
Original Article
Abstract

Compared with male, female non-small cell lung cancer (NSCLC) patients have better response when treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), suggesting a potential association between female hormones and EGFR mutation. However, the results provided by previous studies were inconclusive and controversial. We sought to examine the link between the expression of nuclear female hormone receptors and EGFR mutations in NSCLC.Electronic databases were used to search the relevant articles. The involved hormone receptors included estrogen receptor (ER) and progesterone receptor (PR). The primary endpoint was the occurrence of ER/PR expression and EGFR mutation in NSCLC patients.Five studies fulfilled the criteria and were included in our analysis. Patients with high ER-β expression had higher positive EGFR mutation than low ER-β patients (44.2% vs. 23.7%), and there was a significant difference between the two groups [odds radio (OR) 3.44, 95% confidence interval (CI): 2.40-4.93, Z=6.72, P0.001]. However, there is no significant correlation between EGFR mutations and ER-α (when included ER-α3, OR 1.20, 95% CI: 0.62-2.33, Z=0.55, P=0.58; and when included ER-α4, OR 1.18, 95% CI: 0.62-2.25, Z=0.51, P=0.61) or PR (OR 1.29, 95% CI: 0.40-4.10, Z=0.43, P=0.67). No significant publication bias was observed.High nuclear expression of ER-β, but not ER-α or PR is correlated with EGFR mutations in NSCLC. The underlying mechanism and potential translational relevance warrant further investigation.

Published
2015

26. Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents

Author

He, Qihua, primary, Zhang, Mingzhe, additional, Zhang, Jianrong, additional, Zhong, Shengyi, additional, Liu, Yang, additional, Shen, Jianfei, additional, He, Jiaxi, additional, Jiang, Long, additional, Yang, Chenglin, additional, Zeng, Yuan, additional, Guo, Minzhang, additional, Chen, Xuewei, additional, He, Jianxing, additional, and Liang, Wenhua, additional

Published
2016
Full Text
View/download PDF

27. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.

Author

Wang, Wenjun, Xia, Xiaojun, Wu, Sipei, Guo, Minzhang, Lie, Puyi, and He, Jianxing

Subjects
CANCER treatment, IMMUNOTHERAPY, CLINICAL trials, IMMUNE response, CANCER patients
Abstract

Immunotherapy has become an important approach for treating different tumours which has shown significant efficacy in numerous clinical trials, especially those using new checkpoint inhibitors and adoptive cell therapy, which have rapidly become widespread after being approved. However, analysis of peripheral immune biomarkers before and after immunotherapy and their relationship to clinical responses and disease prognosis have rarely been performed in clinical trials. In this review, we examine dynamic changes in the immune system before and after therapy by analyzing recent clinical trials of immunotherapy in patients with cancer that focused on checkpoint inhibitors and adoptive cell therapy. Our aim was to identify circulating biomarkers which can specifically predict clinical response and prognosis, as well as toxicities of immunotherapy. Through this approach, we hope to advance our understanding of the mechanisms of immunotherapy with the goal of developing individualized treatment for cancer patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

28. [Propensity Score Matching Analysis of VATS Lobectomy and Sublobar Resection for Stage I Lung Adenocarcinoma].

Author

Liu Y, Zhong S, He Q, Zhang J, Chen X, Guo M, and He J

Subjects
Adenocarcinoma of Lung, Adult, Aged, Aged, 80 and over, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Young Adult, Adenocarcinoma pathology, Adenocarcinoma surgery, Lung Neoplasms pathology, Lung Neoplasms surgery, Propensity Score, Thoracic Surgery, Video-Assisted
Abstract

Background: National Comprehensive Cancer Network (NCCN) guidelines recommend video-assisted thoracoscopic surgery (VATS) anatomical lobectomy as the first choice for the treatment of resectable lung cancer. However, sublobar resection offers significantly better functional preservation compared with lobectomy for stage I lung cancer. At present, the inferiority of sublobar resection to lobectomy is still uncertain. Herein, we compared the prognoses of these two types of surgical treatment for stage I lung adenocarcinoma., Methods: Retrospective research was conducted on 258 patients with stage I lung adenocarcinomas who underwent VATS lobectomy and sublobar resection at the First Affiliated Hospital of Guangzhou Medical University between January 2009 and December 2011. VATS lobectomy was performed on 222 patients, and VATS sublobe resection was performed on 36 patients. Propensity score matching analyses were conducted on the two groups., Results: A total of 70 patients were matched in the two groups. No significant difference was observed between the lobectomy and sublobar resection groups after matching (P=0.137). The disease-free survival (DFS) of the two groups were 49.3 and 42.7 months, and their overall survival (OS) were 50.3 and 49.0 months (P=0.122). Further, stratified analysis showed no significant differences in DFS and OS between the two groups with stage Ia lung adenocarcinoma. Nevertheless, the DFS and OS of the two groups significantly differed in matched patients with stage Ib lung adenocarcinomas., Conclusions: Sublobar resection could achieve a similar prognosis to VATS lobectomy for stage Ia lung adenocarcinoma. Lobectomy should still be the first choice for the treatment of stage Ib lung adenocarcinoma.

Published
2017
Full Text
View/download PDF

29. Correlation between epidermal growth factor receptor mutations and nuclear expression of female hormone receptors in non-small cell lung cancer: a meta-analysis.

Author

He Q, Zhang M, Zhang J, Chen Y, He J, Shen J, Liu Y, Zhong S, Jiang L, Yang C, Zeng Y, Guo M, Chen X, He J, and Liang W

Abstract

Background: Compared with male, female non-small cell lung cancer (NSCLC) patients have better response when treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), suggesting a potential association between female hormones and EGFR mutation. However, the results provided by previous studies were inconclusive and controversial. We sought to examine the link between the expression of nuclear female hormone receptors and EGFR mutations in NSCLC., Methods: Electronic databases were used to search the relevant articles. The involved hormone receptors included estrogen receptor (ER) and progesterone receptor (PR). The primary endpoint was the occurrence of ER/PR expression and EGFR mutation in NSCLC patients., Results: Five studies fulfilled the criteria and were included in our analysis. Patients with high ER-β expression had higher positive EGFR mutation than low ER-β patients (44.2% vs. 23.7%), and there was a significant difference between the two groups [odds radio (OR) 3.44, 95% confidence interval (CI): 2.40-4.93, Z=6.72, P<0.001]. However, there is no significant correlation between EGFR mutations and ER-α (when included ER-α3, OR 1.20, 95% CI: 0.62-2.33, Z=0.55, P=0.58; and when included ER-α4, OR 1.18, 95% CI: 0.62-2.25, Z=0.51, P=0.61) or PR (OR 1.29, 95% CI: 0.40-4.10, Z=0.43, P=0.67). No significant publication bias was observed., Conclusions: High nuclear expression of ER-β, but not ER-α or PR is correlated with EGFR mutations in NSCLC. The underlying mechanism and potential translational relevance warrant further investigation.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results